Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387772 | 0.89 | SLC6A5 (0.58) | SLC6A5ACHEPNMTGABRA1GABRA2 | |
| SCHEMBL16264682 | 0.80 | SLC6A5 (0.54) | SLC6A5ACHEMEN1NPC1RAB9A | |
| SCHEMBL17984953 | 0.80 | SLC6A5 (0.54) | SLC6A5ACHEMEN1NPC1RAB9A | |
| SCHEMBL2070858 | 0.80 | SLC6A5 (0.51) | SLC6A5ACHEMEN1NPC1RAB9A | |
| SCHEMBL9256480 | 0.79 | HPGD (0.51) | SLC6A5ACHEMEN1NPC1RAB9A | |
| SCHEMBL22058103 | 0.79 | PNMT (0.42) | PNMT | |
| Hydrochloric Acid SCHEMBL4793706 | 0.78 | HPGD (0.50) | SLC6A5ACHEMEN1NPC1RAB9A | |
| SCHEMBL19643991 | 0.78 | ACHE (0.52) | SLC6A5ACHEMEN1NPC1RAB9A | |
| SCHEMBL31376614 | 0.77 | MEN1 (0.50) | SLC6A5ACHEMEN1NPC1RAB9A | |
| SCHEMBL16264683 | 0.77 | SLC6A5 (0.49) | SLC6A5ACHEMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-113880866-B | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-109689645-B | Cyanoindoline derivatives as NIK inhibitors | 杨森制药有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-113880866-A | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157468-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
| EP-1595881-A1 | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands | Pfizer Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050004129-A1 | Pyrazole derivatives | PFIZER, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040132728-A1 | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | PFIZER INC | 2004-07-08 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | SLC6A5 2934/4885ACHE 1864/4885MEN1 2391/4885 |
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | SLC6A5 1231/4885ACHE 375/4885MEN1 182/4885 |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | SLC6A5 4712/4885ACHE 3836/4885MEN1 1949/4885 |
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | SLC6A5 3148/4885ACHE 2181/4885MEN1 1661/4885 |
| US-20050004129-A1 | Pyrazole derivatives | RTF1, RRM2B, RRM2 | SLC6A5 3779/4885ACHE 3286/4885MEN1 4755/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | SLC6A5 1231/4885ACHE 375/4885MEN1 182/4885 |
| US-20040132728-A1 | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | ADRA1A, ADRA1D, ADRB1 | SLC6A5 3288/4885ACHE 631/4885MEN1 1461/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | SLC6A5 1231/4885ACHE 375/4885MEN1 182/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | SLC6A5 4712/4885ACHE 3836/4885MEN1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.